Lisata Q1 net loss $5.4M; ASCEND Phase 2b data on track for Q4 2024

LISATA THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.65

Cash, equivalents and marketable securities $43.3M as of Mar 31, 2024; funding operations into early 2026.
Net loss $5.4M vs $6.2M in Q1 2023; operating expenses $6.6M, down 3.6% YoY.
Top-line data from pivotal Phase 2b ASCEND trial (mPDAC) expected Q4 2024; full data set mid-2025.
Received FDA Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma.
BOLSTER (cholangiocarcinoma) enrollment completion expected Q3 2024; CENDIFOX on track for year-end 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LISATA THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (reaffirmed).

Period: the three months ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.